Genoway (PA:ALGEN) — Market Cap & Net Worth
Market Cap & Net Worth: Genoway (ALGEN)
Genoway (PA:ALGEN) has a market capitalization of $30.11 Million (€25.75 Million) as of May 4, 2026. Listed on the PA stock exchange, this France-based company holds position #23708 globally and #381 in its home market, demonstrating a -4.40% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Genoway's stock price €2.39 by its total outstanding shares 12339118 (12.34 Million). Analyse Genoway cash flow conversion to see how efficiently the company converts income to cash.
Genoway Market Cap History: 2015 to 2026
Genoway's market capitalization history from 2015 to 2026. Data shows growth from $25.82 Million to $34.48 Million (3.00% CAGR).
Genoway Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Genoway's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.45x
Genoway's market cap is 2.45 times its annual revenue
Latest Price to Earnings (P/E) Ratio
29.54x
Genoway's market cap is 29.54 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $25.82 Million | $10.13 Million | $38.39K | 2.55x | 672.66x |
| 2016 | $25.82 Million | $11.54 Million | $582.23K | 2.24x | 44.35x |
| 2017 | $28.85 Million | $13.16 Million | $1.93 Million | 2.19x | 14.94x |
| 2018 | $31.16 Million | $14.95 Million | $571.65K | 2.08x | 54.51x |
| 2019 | $18.03 Million | $14.28 Million | -$1.04 Million | 1.26x | N/A |
| 2020 | $44.72 Million | $11.02 Million | -$687.30K | 4.06x | N/A |
| 2021 | $61.89 Million | $14.02 Million | -$322.60K | 4.41x | N/A |
| 2022 | $57.70 Million | $17.05 Million | $777.75K | 3.38x | 74.19x |
| 2023 | $66.36 Million | $20.05 Million | $1.57 Million | 3.31x | 42.33x |
| 2024 | $54.10 Million | $22.06 Million | $1.83 Million | 2.45x | 29.54x |
Competitor Companies of ALGEN by Market Capitalization
Companies near Genoway in the global market cap rankings as of May 4, 2026.
Key companies related to Genoway by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Genoway Historical Marketcap From 2015 to 2026
Between 2015 and today, Genoway's market cap moved from $25.82 Million to $ 34.48 Million, with a yearly change of 3.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €34.48 Million | -11.81% |
| 2025 | €39.09 Million | -27.73% |
| 2024 | €54.10 Million | -18.48% |
| 2023 | €66.36 Million | +15.00% |
| 2022 | €57.70 Million | -6.76% |
| 2021 | €61.89 Million | +38.39% |
| 2020 | €44.72 Million | +148.00% |
| 2019 | €18.03 Million | -42.13% |
| 2018 | €31.16 Million | +8.00% |
| 2017 | €28.85 Million | +11.73% |
| 2016 | €25.82 Million | 0.00% |
| 2015 | €25.82 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Genoway was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $30.11 Million USD |
| MoneyControl | $30.11 Million USD |
| MarketWatch | $30.11 Million USD |
| marketcap.company | $30.11 Million USD |
| Reuters | $30.11 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Genoway
genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines… Read more